Diagnostic Microbiology & Infectious Disease
Volume 66, Issue 2 , Pages 187-194 , February 2010

In vitro activity of tigecycline against 2423 clinical isolates and comparison of the available interpretation breakpoints

Received 10 July 2009 ,Accepted 17 September 2009.

References 

  1. Clinical and Laboratory Standards Institute (CLSI) . Performance standards for antimicrobial susceptibility testing: 19th informational supplement (M100-S19). Wayne, Pa: CLSI; 2009;
  2. Cobo J, Morosini MI, Pintado V, Tato M, Samaranch N, Baquero F, et al. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta-lactamase–producing Klebsiella pneumoniae epidemic clone. Diagn. Microbiol. Infect. Dis. 2008;60:319–322
  3. Fritsche TR, Sader HS, Stilwell MG, Dowzicky J, Jones RN. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn. Microbiol. Infect. Dis. 2005;52:187–193
  4. Gales AC, Sader HS, Fritsche TR. Tigecycline activity tested against 11,808 bacterial pathogens recently collected from US medical centers. Diagn. Microbiol. Infect. Dis. 2008;60:421–427
  5. Hawkey P, Finch R. Tigecycline: in-vitro performance as a predictor of clinical efficacy. Clin. Microbiol. Infect. 2007;13:354–362
  6. Keeney D, Ruzin A, Bradford PA. RamA, a transcriptional regulator, and AcrAB, an RND-type efflux pump, are associated with decreased susceptibility to tigecycline in Enterobacter cloacae. Microb. Drug Resist. 2007;13:1–6
  7. Keeney D, Ruzin A, McAleese F, Murphy E, Bradford PA. MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J. Antimicrob. Chemother. 2008;61:46–53
  8. Kelesidis T, Karageorgopoulos DE, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J. Antimicrob. Chemother. 2008;62:895–904
  9. Morosini MI, Garcìa-Castillo M, Coque TM, Valverde A, Novais A, Loza E, et al. Antibiotic co-resistance in extended-spectrum-β-lactamase–producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob. Agents Chemother. 2006;50:2695–2699
  10. Muller A, Coenen S, Monnet DL, Goossens H and the ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe, 1998–2005. Eurosurveillance. 2007;12:3284
  11. Pliatsika V, Afkou Z, Protonotariou E, Sofianou D. In vitro activity of tigecycline against metallo-beta-lactamase–producing Enterobacteriaceae. J. Antimicrob. Chemother. 2007;60:1406–1407
  12. Rodloff AC, Leclercq R, Debbia EA, Cantón R, Oppenheim BA, Dowzicky MJ. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial. Clin. Microbiol. Infect. 2008;14:307–314
  13. Rubino CM, Ma L, Bhavnani SM, Korth-Bradley J, Speth J, Ellis-Grosse E, et al. Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation. Antimicrob. Agents Chemother. 2007;51:4085–4089
  14. Ruzin A, Visalli MA, Keeney D, Bradford PA. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 2005;49:1017–1022
  15. Sader HS, Jones RN, Stilwell MG, Dowzicky J, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn. Microbiol. Infect. Dis. 2005;52:181–186
  16. Souli M, Kontopidou FV, Koratzanis E, Antoniadou A, Giannitsioti E, Evangelopoulou P, et al. In vitro activity of tigecycline against multiple-drug–resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob. Agents Chemother. 2006;50:3166–3169
  17. The European Antimicrobial Susceptibility Testing (EUCAST) Steering Committee . EUCAST technical note on tigecycline. Clin. Microbiol. Infect. 2006;12:1147–1149
  18. Vouillamoz J, Moreillon P, Giddey M, Entenza JM. In vitro activities of tigecycline combined with other antimicrobials against multiresistant Gram-positive and Gram-negative pathogens. J. Antimicrob. Chemother. 2008;61:371–374

PII: S0732-8893(09)00377-0

doi: 10.1016/j.diagmicrobio.2009.09.012

Diagnostic Microbiology & Infectious Disease
Volume 66, Issue 2 , Pages 187-194 , February 2010

Article Tools

* Image Usage & Resolution